NCT04528277 (SCRIPT-LGTB) is a Phase 3 clinical trial of rifapentine plus isoniazid in Infertility, Female, sponsored by Huashan Hospital.

Who is sponsoring NCT04528277?

NCT04528277 is sponsored by Huashan Hospital.

What drugs are being tested in NCT04528277?

Interventions in NCT04528277: rifapentine plus isoniazid.

What condition does NCT04528277 study?

NCT04528277 studies Infertility, Female, Recurrent Implantation Failure, Genital Tuberculoses, Female, Genital Tuberculosis, Latent.

Is NCT04528277 still recruiting?

NCT04528277 is currently status unknown. Last updated 27 August 2020.

Last reviewed 2020-08-27 · How we verify

NCT04528277: SCRIPT-LGTB

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis

Status unknown Phase 3 Last updated 27 August 2020

What this trial tests

Phase 3 trial testing rifapentine plus isoniazid in Infertility, Female in 1,050 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 September 2021

1 September 2022

Quick facts

Lead sponsor	Huashan Hospital
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,050
Start date	1 September 2020
Primary completion	1 September 2021
Estimated completion	1 September 2022
Sites	1 location across China

Drugs / interventions tested

rifapentine plus isoniazid — full drug profile →

Conditions studied

Infertility, Female — all drugs for Infertility, Female →
Recurrent Implantation Failure — all drugs for Recurrent Implantation Failure →
Genital Tuberculoses, Female — all drugs for Genital Tuberculoses, Female →
Genital Tuberculosis, Latent — all drugs for Genital Tuberculosis, Latent →

Sponsor

Huashan Hospital

Who can join

Adults 25 to 40, female only, with Infertility, Female or Recurrent Implantation Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the efficacy, safety and tolerability of the 1-month regimen of three times weekly rifapentine plus isoniazid in improving fertility outcome in recurrent implantation failure (RIF) patients with latent genital tuberculosis (LGTB), compared to no treatment and non-LGTB patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges.
Agbota G, Bonnet M, Lienhardt C. · · 2023 · cited 16× · PMID 36986284 · DOI 10.3390/pathogens12030362

Verify or expand the search:

Other recruiting trials for Infertility, Female

Currently open trials in the same condition.

NCT06771401 — Identification of Biomarkers in Cervical Mucus · NA · recruiting
NCT06984081 — CAPA In-vitro Oocyte Maturation · NA · recruiting
NCT07308561 — The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Under · recruiting
NCT07175571 — SISTER: Sibling Oocyte Insemination With Frozen Sperm From Third Party Donors: Evaluation of Reproductive Techniques · NA · recruiting
NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04528277 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 27 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04528277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing